文献速递妇科肿瘤

PAOLA-1/ENGOT-ov25试验中≥65岁卵巢癌患者维持奥拉帕利联合贝伐珠单抗的疗效与安全性

Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
PubMed 文献 · Eur J Cancer · 2022-12-10

PAOLA-1研究显示新诊断晚期卵巢癌维持治疗中奥拉帕利联合贝伐珠单抗改善无进展生存期。本研究比较≥65岁与<65岁患者,≥65岁患者占36.2%,中位随访22.1个月,≥65岁组中位无进展生存期奥拉帕利组21.6个月 vs 安慰剂组16.6个月(HR 0.55,95%CI 0.41-0.75),与年轻患者相似。≥65岁患者奥拉帕利相关≥3级不良事件发生率与年轻患者相当(36.8% vs 31.7%),高血压和贫血更常见,未发生治疗相关死亡。

要点

  • ≥65岁患者占PAOLA-1随机人群36.2%(292/806)。
  • ≥65岁组中位无进展生存期奥拉帕利组21.6个月 vs 安慰剂组16.6个月(HR 0.55,95%CI 0.41-0.75)。
  • ≥65岁患者奥拉帕利相关≥3级不良事件36.8% vs 年轻患者31.7%,高血压和贫血更常见。

核心结论

  • PAOLA-1中≥65岁患者与年轻患者相比获得相似的无进展生存期获益,安全性特征相似。

研究设计与样本

  • PAOLA-1/ENGOT-ov25(NCT02477644)III期随机研究的事后分析,共806例随机患者,其中292例(36.2%)≥65岁。
  • 比较≥65岁与<65岁患者的基线临床和分子数据及无进展生存期,并评估与奥拉帕利疗效相关的因素和各年龄亚组的安全性。

主要发现

  • ≥65岁患者与年轻患者相比,ECOG体能状态0分比例较低(61.0% vs 76.2%),初始手术比例较低(42.0% vs 55.7%)。
  • ≥65岁患者BRCA1/2突变比例较低(17.1% vs 36.7%),同源重组缺陷阳性比例较低(34.1% vs 55.7%)。
  • 中位随访22.1个月,≥65岁人群中位无进展生存期奥拉帕利组21.6个月 vs 安慰剂组16.6个月(HR 0.55,95%CI 0.41-0.75)。
  • 年轻人群中位无进展生存期奥拉帕利组22.9个月 vs 安慰剂组16.9个月(HR 0.61,95%CI 0.49-0.77)。
  • BRCA突变或同源重组缺陷阳性肿瘤患者中观察到无进展生存期获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. METHODS: Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed. RESULTS: Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41-0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49-0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib. CONCLUSION: Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sabatier R, Rousseau F, Joly F, et al. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2022. PMID: 36634389. doi:10.1016/j.ejca.2022.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。